Conventional Disease-Modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis


 Nine evidence-based guidelines were identified that recommend the use of conventional synthetic disease-modifying antirheumatic drugs as a first-line therapy for patients with rheumatoid arthritis prior to using biologic or Janus kinase inhibitors.
 Methotrexate monotherapy was most commonly recommended drug by included guidelines.
 Eight combination multiple if is ineffective and 4 glucocorticoids in drugs.